LB PHARMACEUTICALS INC (LBRX)
Health Care · Late-stage antipsychotic drug development · NASDAQ
LB Pharmaceuticals is a late-stage biopharmaceutical firm developing LB-102, a novel benzamide candidate aimed at becoming a first-in-class treatment for schizophrenia and mood disorders in the U.S. market.
What LB PHARMACEUTICALS INC does
LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for neuropsychiatric disorders. The company's lead product, LB-102, is a new chemical entity and methylated derivative of amisulpride (a second-generation antipsychotic approved in over 50 countries) currently in pivotal Phase 3 clinical trials for schizophrenia and Phase 2 trials for bipolar depression and major depressive disorder. LB-102 is designed to address limitations of existing antipsychotics with a differentiated therapeutic profile and strong intellectual property protection.
Themes: antipsychotics / schizophrenia, bipolar disorder treatment, major depressive disorder, CNS / neuropsychiatric, Phase 3 clinical trials
Fundamentals
- Price$47.62 as of 2026-08-21 close
- Market cap$1.5B as of 2026-08-21
- P/En/a earnings data not available
- ROE-17.7% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.59 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How LBRX compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How LB PHARMACEUTICALS INC looks technically
LB PHARMACEUTICALS INC (LBRX) is trading 80.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average has held above its 200-day average for at least 29 trading days — a long-sustained "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 43, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 65, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It made a new 20-day high about 3 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 80.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +80.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $36.79 | $36.79 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $26.46 | $26.46 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 35.345. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average has held above its 200-day average for at least 29 trading days — a long-sustained "golden cross", a bullish long-term signal | at least 29 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 43, with buyers in control | 42.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 65, neither overbought (above 70) nor oversold (below 30) | 65.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($42.56 to $49.97) — its "stochastic" reading is 68 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 68.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $49.97 | $49.97 |
|---|---|---|
| From the 52-week high | it is 4.7% below its 52-week high (its highest price of the past year) | -4.7% |
| Above the 52-week low | it is 256.4% above its 52-week low (its lowest price of the past year) | +256.4% |
| Below the 52-week high | it is 4.7% below its highest point of the past year | 4.7% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $49.97 (set on 2026-08-19) | $49.97 |
| Given back of the 52-week move | not available for this company yet | n/a |
| From the all-time high | it is 4.7% below its all-time high | -4.7% |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $13.36 (set on 2025-09-26) | $13.36 |
| Above the all-time low | it is 256.4% above its all-time low | +256.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 83% of the past ~6 months) | 83rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.63 between its high and its low — about 5.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.63 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $35.95 and $52.66 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $35.95 – $44.31 – $52.66 |
| Typical daily range (% of price) | its price moves about 5.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.5% |
| Stretch from the 200-day average | it is trading 8.1 daily ranges above its 200-day average price (80.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.64× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 12.3% since the prior reading | +12.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Open gap | it gapped 2.9% above the previous close 22 sessions ago and has not traded back through the level it left behind at 32.31 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.9% |
| Gap filled | a 2.1% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 45.1 percentage points (the stock gained 47.4% while the market gained 2.3%) | +45.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 67.0 percentage points (the stock gained 70.1% while the market gained 3.1%) | +67.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 89.9 percentage points (the stock gained 100.9% while the market gained 11.1%) | +89.9% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 48% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.4% of the share price. | +48.4% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 56% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $30.55 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | +55.9% |
|---|
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $35.34.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $39.25 and $44.47 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $49.14.
This reading has stood for 6 trading days, since 2026-08-14.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.13 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$51.50 range $37.00 – $78.00; median $49.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LBRX
- Consensus EPS estimate-$0.7983 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical and regulatory risk: LB-102 is a new chemical entity currently in Phase 3 trials; clinical development failure or adverse findings could prevent FDA approval or commercialization","Competition and market acceptance: Multiple branded and generic antipsychotics already dominate the ~$12B US market; physician and patient adoption of LB-102 remains uncertain","Funding and cash runway: Company's continued operations depend on securing adequate financing to complete clinical trials, regulatory submissions, and eventual commercialization"]
What changed in the latest 10-Q
AI-assisted comparison of LBRX's 10-Q filed 2026-05-12 against the prior one filed 2025-11-06.
Risk Factors
- Added:
- Reference to 'unaudited condensed financial statements' in the opening paragraph (newer filing, 2026-05-12)
- Net loss figure for three months ended March 31, 2026 of approximately $19.1 million (newer filing, 2026-05-12)
- Accumulated deficit as of March 31, 2026 of approximately $148.6 million (newer filing, 2026-05-12)
- Reference to 'adjunctive MDD' in the LB-102 clinical development bullet point (newer filing, 2026-05-12)
- Removed:
- Reference to 'financial statements' without 'unaudited condensed' modifier in the opening paragraph (older filing, 2025-11-06)
- Net loss figure for nine months ended September 30, 2025 of approximately $13.7 million (older filing, 2025-11-06)
- Accumulated deficit as of September 30, 2025 of approximately $118.1 million (older filing, 2025-11-06)
- Reworded:
- LB-102 clinical development bullet changed from 'conduct further clinical trials for LB-102 in patients with schizophrenia, initiate clinical development of LB-102 in bipolar depression and other neuropsychiatric indications' to 'conduct further clinical trials for LB-102 in patients with schizophrenia and bipolar depression, and initiate clinical development of LB-102 in adjunctive MDD, and other neuropsychiatric indications' (newer filing, 2026-05-12)
- Notes:
- The financial figures reflect different reporting periods (three months ended March 31, 2026 versus nine months ended September 30, 2025), so direct numerical comparison is not meaningful
- The text provided is truncated at the end of both versions, so comparison is limited to the provided excerpts
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for LBRX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding LBRX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 3,614,632
- Reported value $89,136,835
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
LBRX had 4,746,857 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
LBRX had 14.7% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.8 days to cover at the same settlement.
- Reported short interest (shares) 4,746,857
- Short interest (% of shares outstanding) 14.7%
- Prior settlement (shares) 4,260,793
- Reported change 11.41%
- Days to cover (reported) 12.8
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Janssen Pharmaceuticals (risperidone/Risperdal)
- Eli Lilly (olanzapine/Zyprexa)
- AstraZeneca (quetiapine/Seroquel)
- Allergan (paliperidone/Invega)
- Otsuka (aripiprazole/Abilify)
- Intra-Cellular Therapies
- Perception Neuroscience
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does LB PHARMACEUTICALS INC (LBRX) do?
LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for neuropsychiatric disorders. The company's lead product, LB-102, is a new chemical entity and methylated derivative of amisulpride (a second-generation antipsychotic approved in over 50 countries) currently in pivotal Phase 3 clinical trials for schizophrenia and Phase 2 trials for bipolar depression and major depressive disorder.
What sector is LB PHARMACEUTICALS INC (LBRX) in?
LB PHARMACEUTICALS INC (LBRX) is classified in the Health Care sector. Its industry is Late-stage antipsychotic drug development. It trades on NASDAQ.
Who are LB PHARMACEUTICALS INC's (LBRX) competitors?
Notable peers of LB PHARMACEUTICALS INC (LBRX) include Janssen Pharmaceuticals (risperidone/Risperdal), Eli Lilly (olanzapine/Zyprexa), AstraZeneca (quetiapine/Seroquel), Allergan (paliperidone/Invega) and Otsuka (aripiprazole/Abilify). This peer set is informational only — not financial advice.
Is LB PHARMACEUTICALS INC (LBRX) overbought or oversold right now?
LB PHARMACEUTICALS INC (LBRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 65, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LBRX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.